Narrow search
Showing 1 - 6 of 6
Cover Image
How can a joint European health technology assessment provide an "additional benefit" over the current standard of national assessments?
Julian, Elaine; Gianfrate, Fabrizio; Sola-Morales, Oriol de - In: Health economics review 12 (2022) 1, pp. 1-12
Objectives: We conducted a multi‑stakeholder survey to determine key areas where a joint European health technology assessment (HTA) could provide "additional benefit" compared to the status quo of many parallel independent national and subnational assessments. Methods: Leveraging three...
Persistent link: https://www.econbiz.de/10013329416
Cover Image
Shaping a research agenda to ensure a successful European health technology assessment : insights generated during the inaugural convention of the European Access Academy
Julian, Elaine; Pavlovic, Mira; Sola-Morales, Oriol de; … - In: Health economics review 12 (2022) 1, pp. 1-15
Objectives: Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealing with remaining uncertainties as well as transparent...
Persistent link: https://www.econbiz.de/10013492801
Cover Image
Shaping a research agenda to ensure a successful European health technology assessment: Insights generated during the inaugural convention of the European Access Academy
Julian, Elaine; Pavlovic, Mira; de Sola-Morales, Oriol; … - In: Health Economics Review 12 (2022) 1, pp. 1-15
Objectives: Key challenges for a joint European Health Technology Assessment (HTA) include consolidated approaches towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease, dealing with remaining uncertainties as well as transparent...
Persistent link: https://www.econbiz.de/10014489950
Cover Image
Patient relevant endpoints in oncology: Current issues in the context of early benefit assessment in Germany
Dabisch, Inna; Dethling, Jürgen; Dintsios, … - In: Health Economics Review 4 (2014) 2, pp. 1-8
The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the new medicines compared to an appropriate comparator as defined by the...
Persistent link: https://www.econbiz.de/10011599811
Cover Image
Patient relevant endpoints in oncology : current issues in the context of early benefit assessment in Germany
Dabisch, Inna; Dethling, Jürgen; Dintsios, … - In: Health economics review 4 (2014) 2, pp. 1-8
The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the new medicines compared to an appropriate comparator as defined by the...
Persistent link: https://www.econbiz.de/10010528451
Cover Image
Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany
Dabisch, Inna; Dethling, Jürgen; Dintsios, … - In: Health Economics Review 4 (2014) 1, pp. 1-8
D61; H51; I18. </AbstractSection> Copyright Dabisch et al.; licensee Springer. 2014
Persistent link: https://www.econbiz.de/10010998823